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Microbiological profiles of sputum 
and gastric juice aspirates in Cystic 
Fibrosis patients
H. Al-momani1, A. Perry2, C. J. Stewart3, R. Jones1, A. Krishnan1, A. G. Robertson1, S. Bourke4, 
S. Doe4, S. P. Cummings5, A. Anderson4, T. Forrest4, S. M. Griffin4, M. Brodlie1, J. Pearson1 & 
C. Ward1
Gastro-Oesophageal Reflux (GOR) is a key problem in Cystic Fibrosis (CF), but the relationship between 
lung and gastric microbiomes is not well understood. We hypothesised that CF gastric and lung 
microbiomes are related. Gastric and sputum cultures were obtained from fifteen CF patients receiving 
percutaneous endoscopic gastrostomy feeding. Non-CF gastric juice data was obtained through 
endoscopy from 14 patients without lung disease. Bacterial and fungal isolates were identified by 
culture. Molecular bacterial profiling used next generation sequencing (NGS) of the 16S rRNA gene. 
Cultures grew bacteria and/or fungi in all CF gastric juice and sputa and in 9/14 non-CF gastric juices. 
Pseudomonas aeruginosa(Pa) was present in CF sputum in 11 patients, 4 had identical Pa strains in 
the stomach. NGS data from non-CF gastric juice samples were significantly more diverse compared 
to CF samples. NGS showed CF gastric juice had markedly lower abundance of normal gut bacteria; 
Bacteroides and Faecalibacterium, but increased Pseudomonas compared with non-CF. Multivariate 
partial least squares discriminant analysis demonstrated similar bacterial profiles of CF sputum 
and gastric juice samples, which were distinct from non-CF gastric juice. We provide novel evidence 
suggesting the existence of an aerodigestive microbiome in CF, which may have clinical relevance.
Cystic Fibrosis (CF) is the most common recessively inherited condition in the Caucasian population1. Seminal 
reports from the 1930s described pancreatic abnormalities and steatorrhea, with the disease initially known as 
“Cystic fibrosis of the pancreas”2.
 In the modern era CF is recognised as a multi-system disorder. Most of the morbidity and premature mortal-
ity associated with CF can be attributed to chronic lung diseases caused by microbial infections and subsequent 
inflammation3, most frequently by Pseudomonas aeruginosa (Pa)4. Treatment from dedicated CF centres has been 
associated with increased survival and treatment of lung disease is an understandable priority. The overall bene-
fits associated with dedicated CF centres however emphasise a multi-disciplinary approach, and gastrointestinal 
problems are recognised as prominent. In particular Gastro-Oesophageal Reflux (GOR) is increased with a prev-
alence of more than 50%5. Several mechanisms have been proposed including reduced lower oesophageal sphinc-
ter pressure (LOS), increased transient LOS relaxation, and delayed gastric emptying. Increased GOR might also 
be due to an increased abdomino-thoracic pressure gradient during cough and physiotherapy6.
A relationship between aspiration of gastric contents during a reflux event and deterioration of lung function is 
implied by the finding of poorer lung function in CF patients with acid reflux7. Anti-reflux medications have been 
associated with improved respiratory symptoms and lung function and anti-reflux surgery with a slower lung 
function decline and significant decrease in CF exacerbations8. However it has also been suggested in a scarce 
literature that treatment with the proton pump inhibitor esomeprazole (PPI) may be associated with earlier and 
more frequent exacerbations compared with placebo9.
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The potential importance of an aero-digestive microbiome has long been the subject of interest in respiratory 
and gastrointestinal medicine in situations other than CF. Multiple reports provide evidence that a gastric reser-
voir is a risk factor for acquiring nosocomial pneumonia in the intensive care unit (ICU) setting10. Studies have 
also been carried out in elderly, non-CF patients which report both concordance between gut and respiratory 
bacteria and a high prevalence of bacteria present in the gut prior to their presence in the respiratory tract11. This 
data is consistent with a link between gastric and lower respiratory tract bacterial colonisation in ICU patients 
fed by nasogastric tube12.
The microbial colonisation of stomach contents in CF patients and its potential to act as a reservoir for micro-
organisms known to cause lung infection is not completely understood. We therefore undertook a study of the 
microbiology of CF lung and gastric contents. Our hypothesis was that bacterial flora in sputum would be related 
to that in gastric aspirate.
Methods
Ethical approval. This study was adopted by the Hepatopancreatobiliary and Gastroenterology Biobank, 
Newcastle University and approved by the Newcastle & North Tyneside 1 Research Ethics Committee (UK). All 
study participants provided written informed consent prior to initiation of the study. All methods were carried 
out in accordance with relevant guidelines.
Symptoms of extraoesophageal reflux. Patients with CF had symptoms of extraoesophageal 
reflux (EOR) assessed using the Reflux Symptoms Index (RSI) score; score less than 13 classed as not EOR 
symptomatic13.
CF gastric juice and sputum samples. CF patients receiving percutaneous endoscopic gastrostomy 
(PEG) feeding represented an important opportunity to directly sample gastric juice, with less potential for con-
tamination with oropharnygeal commensals. Only adult stable CF patients receiving PEG tube feeding, from the 
270 CF patients attending the regional CF Centre, were therefore included in this study; potentially 18 patients 
from the regional clinic population. Following overnight fasting, gastric juice was collected from 15 sequential 
patients who attended the clinic during the course of the study between 22/05/2013-17-04/2014, 83% of all the 
potentially available patients with PEG tubes in the region were therefore included in this study. No PEG fed CF 
patients were excluded or positively selected for the study (Table 1).
In brief, 10 ml of sterile saline was injected through the PEG and aspirated after 2-3 minutes. Spontaneously 
expectorated sputum (n = 13) and cough swabs (n = 2) were also obtained.
Gastric juice pH was measured using pH strips and sputum samples were homogenised with equal amounts 
of dithiothreitol for 1 to 3 minutes.
Collection of non-CF gastric juice samples. Following fasting (≥ 8 hours) gastric juice was collected 
from 14 patients without CF undergoing routine upper gastro-intestinal endoscopy performed according to 
British Society of Gastroenterology guidelines, by suctioning gastric juice through the endoscope (Table 2). 
All patients were requested to stop any acid suppression medication 2 weeks before the endoscopy procedures. 
Sputum was not collected from the non-CF patients.
Gastric juice and sputum samples microbial study. Gastric juice and sputum samples underwent 
microbiological culture performed in accordance with UK standard methods. An aliquot was stored at − 20 °C 
for DNA extraction.







CF-1 F508del/F508del 26 17 Yes 6 2.0L (52%) 19.9 22 Azith Inh Coli Inh Tob
CF-2 F508del/F508del 27 20 Yes 2 1.7 (42%) 23.2 70 Azith Fluclox Inh coli
CF-3 F508del/F508del 20 25 Ranitidine 3 0.8L (26%) 19.5 28 Azith Fluclox Inh Coli
CF-4 F508del/F508del 24 36 Yes 6 0.76L (28%) 19 154 Azith Inh Coli
CF-5 F508del/F508del 41 NA [died] Yes 5.5 0.45L (18%) 18.2 65 Azith Inh Tob
CF-6 F508del/F508del 31 16 Yes 6 0.5L (12%) 19.1 70 Azith Inh Coli
CF-7 F508del/ R117H 22 16 Yes 3 2.7L (66%) 16.4 14 Fluclox
CF-8 I507del/ Arg560Lys 18 13 Yes 2 3.5L (88%) 19.4 37 Fluclox Inh Coli Inh Tob
CF-9 F508del/R117H 30 14 Yes 6 1.55L (46%) 17.8 56 Fluclox Inh Coli
CF-10 F508del/F508del 25 17 Yes 2 1.7L (38%) 15.9 98 Azith Fluclox Inh Tob
CF-11 F508del/G542X 32 NA [PEG removed] No 2 1.15L (36%) 19.4 112 Azith Inh Coli
CF-12 F508del/F508del 30 19 Yes 6 1.2L (29%) 19.8 115 Azith Fluclox Inh Coli
CF-13 F508del/G542X 24 15 Yes 2 1.65L (36%) 15.24 197 Azith Inh Coli Inh Tob
CF-14 F508del/ Arg851Ter 23 22 Yes 6 2.3L (59%) 20.2 56 Azith
CF-15 G542X/G551D 22 NA [moved country] Yes 2 0.85L (28%) 18 42 Azith Inh Coli
Table 1.  Demographic data for CF patients. Azith = oral azithromycin long-term. Fluclox = oral 
flucloxacillin long-term. Inh Coli = inhaled colistin (nebulised or inhaler). Inh Tob = inhaled tobramycin 
(nebulised or inhaler). RSI score = Reflux symptom index score, < 13 normal. NA = not available.
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10 μ L of homogenised sputum and gastric juice were plated for bacterial and fungal cultures. The following 
media were used: Columbia blood agar supplemented with 5% horse blood, chocolate agar supplemented with 
70 mg/L bacitracin, Burkholderia selective agar (for CF sputa and gastric juice, CEP bioMérieux UK), Cysteine 
lactose electrolyte deficient agar (CLED) and fastidious anaerobic agar (FAA). Plates were incubated according to 
standard protocol, CEP cultures were incubated for 10 days at 30 °C for isolation of Burkholderia cepacia complex 
and rapidly growing mycobacterium.
Plates were examined daily for evidence of microbial growth and assessment of the number of distinct colo-
nial variants was recorded. All morphological variants were sub-cultured and used for identification and stored 
at − 20 °C in 10% glycerol skimmed milk. Isolates were identified by matrix assisted laser desorption ionisation 
time-of-flight (MALDI-TOF) mass spectrometry (Bruker Daltonics, UK) and where necessary, appropriate API 
kits (bioMérieux, UK)14. Mycobacterium was identified by rpoB, sodA and hsp65 gene sequencing and strain 
typed using variable number tandem repeat (VNTR), (Colindale, UK15). All isolates of Pa were typed via VNTR 
profiling16.
DNA extraction. DNA extraction was performed from sputum and gastric juice samples using a PowerSoil™ 
DNA Isolation Kit (MoBio) in accordance with the manufacturer’s instructions.
Molecular based studies. Bacterial profiling utilised the 16S rRNA gene targeting variable region 4 (V4) 
based on the Schloss wet-lab MiSeq SOP (http://www.mothur.org/wiki/MiSeq_SOP). Raw fastq data were pro-
cessed using Mothur (version 1.31.2) as described in the MiSeq SOP17. Chimeric sequences were detected by 
Chimera.uchime and removed from downstream analysis. Alignment was generated via the Silva database18. A 
cutoff of 70 was applied to assign sequences to the trainset_ 9_032012 resulting in 2,228,291 reads. All sequences 
were deposited in MG-RAST under the accession numbers 4603845.3 - 4603893.3.
Statistical analysis. NGS profiles were analysed by multivariate partial least squares discriminant analysis 
(PLS-DA) (SIMCA 13.0 software, Stockholm, Sweden)19. PLS-DA uses assigned variables to interrogate data for 
maximum variance. To check data was adhering to multivariate normalities, Hotelling’s T2 tolerance limits were 
calculated and set at 0.95.
Results
CF Patients. We sampled over 80% of all the PEG patients potentially available in the North East Region 
of England. This patient cohort had severity of CF lung disease in keeping with this population (median FEV1, 
1.55 L range 0.45–3.5 L) along with long term antibiotic exposure and use of acid suppression medication for all 
patients (Table 1).
Microbial culture. Routine microbial culture was positive for bacteria and/or fungi in all CF gastric juice and 
sputum samples. All samples had more than one organism isolated except a gastric juice sample from CF-8 that 
only had Candida albicans. See table E1 and E2 in the online data supplement for CF gastric juice and CF sputum 
samples culture results.
Symptoms of extraoesophageal reflux in CF patients. Symptom scores for extraoesophageal reflux 
were available in 12 of the 15 patients with CF (Table 1). All patients were EOR symptomatic, with an RSI 
score > 12; median RSI score 17 (range 13–36).
Patient No Age/yrs Background disease PPI yes/no* Gastric juice pH
1 75 Oesophagitis yes 2.4
2 56 Oesophagitis and Pyloroplasty yes 6.6
3 65 Barrett’s Oesophagus and Hiatus Hernia no 4.8
4 59 Hiatus Hernia yes 2
5 45 Oesophagitis and Hiatus Hernia n/a 1.4
6 42 Gastritis and Hiatus Hernia yes 5.5
7 58 Oesophagitis and Hiatus Hernia yes 4
8 80 Not known n/a 4.7
9 50 Gastric ulcer yes 8.4
10 78 Gastritis and Hiatus Hernia n/a 1.6
11 73 Barrett’s Oesophagus yes 5.1
12 55 Not known n/a 5.2
13 68 Duodenal ulcer n/a 6
14 65 Gastritis n/a 1.7
Table 2.  Demographic data for the non-CF patients. All patients were off PPI or any other acid suppression 
medication 2 weeks before endoscopy procedure.
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CF gastric juice vs sputum samples culture results. Nine of the 15 CF patients included in this study 
had one or more microorganism (fungal or bacteria) common between sputum and gastric juice samples, 
5 had at least one bacteria taxa common between sputum and gastric juice while 4 had one or more fungal spe-
cies. Among the bacterial common between sputum and gastric juice were, Pa (4/9), Streptococcus spp (2/9) and 
Achromobacter spp. (2/9). Conversely, 6 patients had microorganisms isolated in both gastric juice and sputum, 
with no organism common to both samples.
All CF patients had fungal species isolated in either sputum or gastric juice samples, this included 8 patients 
with Candida spp. One patient had Aspergillus spp. isolated in both gastric and sputum samples.
CF gastric juice vs non-CF gastric juice culture results. Microorganisms, either bacterial or fungal, 
were isolated from all 15 CF gastric juice samples. No microorganisms were isolated from 5 of the 14 non-CF 
gastric juice samples. (see Table E3).
Bacterial species were detected in 11/15 CF gastric juice samples (mean 2.2 bacterial isolates/patient). 
Streptococcus spp. (4/15), Pa (4/15), Lactobacillus spp. (4/15), and Staphylococcus spp. (3/15) were the most fre-
quent bacteria isolated. Bacterial species were detected in 8/14 non-CF gastric juice samples (mean 2.2 bacteria 
isolates/patient). Streptococcus spp (4/14), Lactobacillus spp (2/14) Staphylococcus spp (2/14) were the most fre-
quently isolated. Pa was detected in only one patient, without CF or other underlying lung disease. Fungal patho-
gens were detected in all CF gastric juice samples (mean of 2 fungi /patient), Candida spp were isolated from only 
3 out of 14 non-CF gastric juice samples.
Pseudomonas aeruginosa. Pa was detected in 11 of the 15 CF sputa (73%) (CF-1, CF-5, CF-6 and CF8-15) and 
in 4 of the 15 CF gastric juice samples (26%) (CF-1, CF-5, CF-12 and CF-15). CF-1 and CF-12 had both mucoidal 
and non-mucoidal Pa in both sputum and the gastric juice, CF-5 had mucoidal and non-mucoidal Pa in sputum 
and only mucoidal Pa in gastric juice, CF-15 had only mucoidal Pa in sputum and gastric juice.
The median age of patients with and without Pa was 26 (range 20–27) and 23 (range 18–41) respectively. The 
median FEV1 for patients with Pa was 1.55L (range 0.45–3.5L) compared to 1.25L (range 0.8–2.7L) in non Pa 
infected patients.
Variable number tandem repeat (VNTR) analysis of Pa showed that Pa strains isolated from gastric juice 
and sputum samples were identical in 3 of the 4 patients who cultured Pa in both gastric juice and sputum. The 
remaining CF patient with Pa in gastric juice and sputum (CF-1) also appeared to have matched strains of Pa 
in both sputum and gastric juice. However, in addition, this patient also had other strains of Pa present only in 
sputum samples and not isolated in gastric juice.
Next Generation Sequencing. Fourteen non-CF gastric juice (GJ 1-14), 13 CF gastric juice (CF-GJ 1, 2, 
4-12, 14, 15) and 12 CF sputum samples (CFS 4-15) had microbiome analysis using NGS. Non-CF gastric juice 
showed higher diversity compared to the CF gastric juices and sputum samples (Fig. 1A). Proteobacteria were 
abundant in both CF gastric juice and CF sputum samples (72% and 74% of relative abundance, respectively) 
whereas Firmicutes were more abundant in non-CF gastric juice (48%).
The average Shannon diversity indices (H’) was significantly higher in non-CF gastric juice than CF gastric 
juices (P = 0.002) and CF sputum (P = < 0.001). The H’ of CF gastric juice and sputum samples were not different 
(P = 0.93: Fig. 1B).
PLS-DA of all samples demonstrated that both gastric juice and sputum samples from patients with CF had 
comparable profiles, which was distinct from non-CF gastric juice (Fig. 2). CF samples showed a relative low aver-
age of Shannon diversity making them cluster near the origin of PLS-DA plots, while non-CF gastric juice samples 
Figure 1. (A) Bar plot showing the relative abundance of each operational taxonomic unit (OTU) within 
non-CF gastric juice (GJ), CF gastric juice (CFGJ), and sputum samples (CFS). (B) Shannon Diversity Index of 
CF samples (CFGJ and CFS) and non-CF GJ.
www.nature.com/scientificreports/
5Scientific RepoRts | 6:26985 | DOI: 10.1038/srep26985
showed high diversity. Further analysis of the matched gastric juice and sputum samples from the same patient 
showed these samples generally grouped together (see Figure E1 in the data supplement). The loading plot from 
the PLS-DA of the overall bacterial community revealed that Prevotella, Rothia, Streptococcus, Staphylococcus, 
Herminiimonas and Pseudomonas were closely associated with CF samples while Faecalibacterium, Roseburia, 
Bacteroides, and Lactobacillus were more associated with non-CF gastric juices (see Figure E2 in the data 
supplement).
Discussion
We believe this is the first study directly comparing microorganisms isolated from the airways and gastric juice in 
the same PEG fed CF patients. We showed that the digestive tract and airways were populated by bacteria which 
were sometimes identical and of known importance in CF lung disease, including biofilm forming strains of Pa. 
This highlights the possibility that the stomach constitutes a viable bacterial reservoir, relevant to the overall 
pathophysiology of CF20.
We found that gastric juice samples from adult CF patients were significantly different from non-CF gastric 
juice samples. At a molecular level, NGS of CF gastric juice showed a much lower abundance of bacteria than typ-
ically found in the normal stomach, with CF gastric juice containing Bacteroides, Faecalibacterium and increased 
amounts of Pa compared with the non-CF controls21. The results obtained from our non-CF gastric juice samples 
were in accordance with the known make-up of the normal gastric microbiota22.
In all cases where Pa was found concordantly in CF gastric juice and sputum we demonstrated genetically 
identical strains by VNTR. If lung and stomach were colonised by Pa from unrelated, stochastic sources, the 
organisms would be highly unlikely to be identical at the molecular level. In CF patients with intermittent coloni-
zation or recently acquired chronic Pa infection, there are high levels of genotype diversity23, suggesting that CF 
patients acquire unique Pa strains independently, from different environmental sources24. For intermittently col-
onized patients, following initial eradication by inhaled antibiotic treatment, recolonization by Pa can occur. This 
can be with a different genotype, suggesting new environmental sources, but in approximately 25% of patients 
the same genotype is identified, suggesting either undetectable persistent colonisation or local unknown envi-
ronmental sources of recolonization23. Careful longitudinal eradication studies in CF have observed patients 
being re-colonized with the original Pa strains after several years of no demonstrable Pa in sputa25. The findings 
reported in this study might be consistent with the notion that gastric contents may represent a niche, relatively 
protected from inhaled antibiotics used in best practice eradication protocols26.
Our PEG tube gastric juice sampling eliminated the possibility of contamination by upper gastro intestinal 
tract and respiratory flora. These are potential considerations for other sampling procedures, such as endoscopy. 
Our data unambiguously confirms the ability of bacteria to survive in the stomach, constituting a potential res-
ervoir of viable pathogens relevant to CF disease. Reflux and aspiration events have been widely documented in 
CF patients27, and our CF patients had symptoms of extraoesophageal reflux beyond the normal range. Our data 
might therefore be consistent with the possibility that microorganisms relevant to CF lung pathophysiology could 
be aspirated.
It is also likely that gastric juice Pa may derive from swallowed sputum containing Pa that is cleared from the 
lung following cough. We found one patient where identical Pa was found in sputum and gastric juice but where 
Figure 2. Partial least square discriminant analysis (PLS-DA) score scatter plot of all samples. Non-CF 
gastric juice – GJ; CF gastric juice – CFGJ; Sputum samples – CFS. The Axes represent a % of variance. The CF 
gastric juice and sputum samples show a close relationship. In contrast the Gastric Juice samples from control 
patients are widely variable and clearly distinct from the CF sputum and gastric juice clustering.
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the sputum sample also contained Pa not isolated in gastric juice. Alongside our finding of Pa in the gastric juice 
of a control subject without lung disease, our data indicate that although Gastric juice Pa may be swallowed 
following mucocilliary clearance of a diseased airway, Pa could be derived through diverse routes and sources, 
including but not restricted to microaspiration for lung Pa.
It has long been recognised that as well as refluxing, even healthy adults may aspirate oropharyngeal secre-
tions, especially during reclined sleep. An indium 111 chloride technique from 1978 showed that 45% of nor-
mal subjects aspirated during deep sleep, and that in patients with “depressed consciousness”, aspiration was 
detectable in 70% of patients28. This study noted the potential for bacterial pneumonia as a result of failed 
clearance of aspirated bacteria. A further valuable quantitative study by Gleeson and colleagues employed 
infusion of 2 mL/h radioactive Tc-99m tracer into the nasopharynx to estimate the quantity of occult aspira-
tion of nasopharyngeal secretions in normal humans. Aspiration was common, occurring in 50% of healthy 
young men during sleep, and was variable within subjects studied on more than one occasion. The levels of 
aspiration measured were 0.01 to 0.2 mL; levels noted as being consistent with a potentially significant bacterial 
inoculum29.
Microbiological continuity of the aerodigestive tract, using culture independent methods has also previously 
been suggested in healthy adults indicating that microaspiration may be common in healthy individuals30. An 
association between GOR and lower respiratory tract Pa colonisation in children with CF is also consistent with 
potential gastric immigration31. More recently in children with chronic cough undergoing bronchoscopy and 
gastrointestinal endoscopy 8 of the most abundant bacteria in the gastric fluid were shown to be abundant in the 
lungs. The authors concluded that this represented evidence of microbiological exchange between the lung and 
the gastrointestinal tract, independent of the oropharyngeal microbiome32.
It is of interest that molecular epidemiology studies in CF lung transplant recipients show that lung allografts 
become recolonized with the same clone of Pa cultured before transplantation33. This recolonization is believed 
to originate from the upper airway and the sinuses34. It is also possible that the lungs of CF patients might be 
vulnerable to infection from aspiration of Pa colonising the gastrointestinal tract post transplantation however35, 
and that bi-directional transmission of pathogenic organisms, including Pa, occurs between the stomach and the 
oropharynx12. In lung transplantation, GOR has been substantially implicated as a potential non-alloimmune 
cause of Bronchiolitis Obliterans Syndrome (BOS), and anti-reflux fundoplication surgery has been assessed36, 
and associated with improved allograft function37.
Molecular methods have previously demonstrated that gastric microbiome diversity is normally high 
and similar to that described for the lower gastrointestinal tract22,38. Decreasing airway bacterial diversity in 
patients with CF is well described39 . This is potentially consistent with our study showing that the CF gastric 
microbiota showed lower diversity compared to non-CF in the molecular based approach. This loss of diver-
sity was a common feature between sputum and CF gastric juice samples compared to non-CF gastric juices. 
Molecular identification and multivariate discriminant analysis showed that the CF gastric juice samples and 
sputum samples were clustered and distinct from the non-CF gastric juices. Moreover, sputum and CF gastric 
juice samples from the same patient also had comparable profiles. Overall this further suggests that a link 
may be present between microbes colonising the sputum and gastric juice in some CF patients and that this is 
worthy of further investigation. Such studies should investigate whether the same profile of micro-organisms 
in the sputum and the gastric juice we observed might be explained by a common origin in the sinus and/or 
oro-pharynx.
There are limitations to our study inherent to a real world clinical setting and our study design. We restricted 
our gastric juice sampling to PEG fed patients and sampled over 80% of all the PEG patients potentially available 
to us, but this limited our study and our reported data to a specific patient cohort. There was no exclusion based 
on severity of the disease or antibiotic exposure. It is relevant to consider that apart from PEG fed patients with 
CF we have previously isolated Pa from samples of gastric juice from non- PEG fed CF patients, where gastric 
juice was sampled by endoscopy35. Our previous study found strains of Pa identical at the molecular level in bron-
cho alveolar lavage (BAL), endoscopically sampled gastric juice and sputa. This suggests that the findings of our 
present study, that the stomach constitutes a viable bacterial reservoir relevant to the overall pathophysiology of 
CF, is not restricted solely to PEG fed patients35.
We also recognise that long term antibiotic exposure and use of Proton Pump Inhibitors (PPIs) in our patients 
could impact on the gastric juice microbiology that we observed. Use of PPIs is increasingly recognised to be 
associated with alterations in the gastric, lung, and oropharyngeal Microflora32. The importance of this is a source 
of current debate however, to which we have contributed40.
Gastric acid (GA) inhibition via proton pump inhibitors or histamine-2 receptor antagonists is prescribed to 
CF patients when fat absorption remains insufficient despite an adequate dosage of pancreatic enzyme replace-
ment41. Gastroesophageal reflux disease is another reason to start drugs for GA inhibition in patients with CF, 
and in North America it has been observed that the majority of patients with CF are on gastric acid suppressive 
treatments42. According to the clinical practice in our centre of study and that of others, all our CF patients were 
therefore on acid suppression therapy. Antibiotic therapy is also a current mainstay of therapy in CF. We feel that 
further studies regarding the effect of antibiotics and anti-acid therapy on the aerodigestive microbiome in CF, 
though challenging, could be important. We hope that such work may be aided and informed by our present 
study data.
In summary, we have shown a novel association between the sputum and gastric juice microbiome of CF 
patients. This study demonstrates that the stomach may represent an under recognised foci of bacterial infection, 
and potential reservoir of Pa in CF. Gastric microbiology could be contributed to by cough, expectoration and 
swallowing of organisms from the lung. Patients with CF are also known to reflux and aspirate however, indicat-
ing that in principle gastric microorganisms could contribute to the lung compartment. We conclude that the 
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‘aerodigestive microbiome’ may have potential relevance in the pathophysiology of CF and may have therapeutic 
implications, since Pa eradication does not consider a gastric niche of organisms.
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